#Checkmate 9la clinical study trial#

EDT and featured in the official press program during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.įor the combination of Opdivo plus chemotherapy, median OS was 15.4 months vs. The data will be presented in an oral session on Saturday, Jfrom 1:45 p.m. Opdivo plus Yervoy is the first dual immunotherapy combination to demonstrate a superior survival benefit versus chemotherapy in this setting. PRINCETON, N.J.-(BUSINESS WIRE)- Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 CheckMate -648 trial, in which two Opdivo-based treatment combinations - Opdivo (nivolumab) plus chemotherapy and Opdivo plus Yervoy (ipilimumab) - demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit compared to chemotherapy at the pre-specified interim analysis in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression ≥1%, as well as in the all-randomized population. Not intended for media in the UK & Ireland

#Checkmate 9la clinical study trial#

Opdivo demonstrated significant overall survival benefit over chemotherapy alone in both PD-L1 positive and all-randomized populations in both treatment armsĬheckMate -648 marks the third global trial in which Opdivo demonstrated a significant benefit for patients with upper gastrointestinal cancersĭata to be featured in an oral presentation during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting